Menu
Washingtoner
  • Home
  • Health
  • Business
  • Books
  • Artificial Intelligence
  • Society
  • Construction
  • Financial
  • Longevity
Washingtoner

Seagen Statement on Outcome of Daiichi Sankyo Arbitration
Washingtoner/10182820

Trending...
  • Spokane: 'Bike the Bridge' Ahead of Maple Street Reopening
  • Tacoma: Applicants Sought for the Human Services Commission
  • City of Tacoma Launching New Voluntary Demolition Salvage Program to Promote Resource Reuse and Streamline Permitting
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.

"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."

More on Washingtoner
  • Vierra Communities Adds Operations of Two Skilled Nursing Facilities in the DC Metro Area
  • Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
  • Webinar Announcement: Built for Trust: Latitude's 0 to 1 Compliance Playbook for Modern Cross-Border Payments
  • OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
  • Dentists launch independent platform to help practices choose the right technology

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

More on Washingtoner
  • Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • Spokane: SPD is Investigating a Shooting that Occurred Early Monday
  • Tacoma Residents Report Improved Satisfaction in 68 of 80 City Service Areas in 2026 Community Survey
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026

Contacts

For Media

David Caouette
(310) 430-3476
dcaouette@seagen.com

For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • Morrisville & Cary Education Centers Honored with National Award
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Henri-Lloyd Launches Sail Free to Break Down Barriers to Sailing
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park
  • Destination Niagara Launches Game Changing Digital Magazine Redefining How Visitors Experience Niagara Falls
  • San Diego's newest marketing firm is boring on purpose — it's working
  • Arizona Christian Homeschools Launches Statewide Directory
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It
  • Senco Home Services Expands Residential Construction Services
  • Ricci's Painting & Contracting Expands Home Transformation Services
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Tacoma: Applicants Sought for the Human Services Commission
  • Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy
  • Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
  • Verbica Challenges Panetta to a Televised Debate on the Issues
  • Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
  • SPD Seeking Assistance Regarding Motorcycle Collision in North Spokane
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
_catLbl0 _catLbl1

Popular on Washingtoner

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 297
  • Tacoma: Homicide Investigation – 800 Block of Martin Luther King JR Way
  • Spokane: Community Days At City Council Celebrating Student Civic Engagement
  • City of Tacoma Attracts More Affordable Housing to Proctor Neighborhood
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • Tacoma Dome Welcomes Class of 2026
  • P-Wave Classics Opens Pre-Orders for Volume II of Robert Bage's Hermsprong
  • City of Spokane Launches New Webpage, Notice Document to Connect Residents with Eviction Prevention Resources
  • A Foundational Claim in Human Secrecy Goes Public
  • City of Tacoma to Implement Temporary Road Closures and Traffic Restrictions on June 12

Similar on Washingtoner

  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
  • Webinar Announcement: Built for Trust: Latitude's 0 to 1 Compliance Playbook for Modern Cross-Border Payments
  • OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
  • Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • Allstream Energy Partners Expands AI-Optimized Website Development Division to Meet Growing Demand in GEO / AEO Services
  • America's Workforce Solution Named an OpenAI SMB Channel Partner, Bringing Enterprise-Grade AI to Main Street
  • Data Tiles Introduces the Decision-Driven Enterprise to North America
  • eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute